Berkshire Hathaway Cash Falls as Abel Boosts Stock Buybacks 
OpenAI Restricts Astra AI Over Cyberattack Risks 
Austal Shares Surge 16% as Hanwha Offers Up to $1.2 Billion for U.S. Shipbuilding Business 
Nintendo Shares Jump as Switch 2 Sales Boost Earnings 
Treasury Wine Estates Shares Jump as U.S. Overhaul Lifts FY2026 Outlook 
Deutsche Bank Upgrades Persimmon to Buy After Strong First-Half Results 
ADNOC Gas Targets Up to $4B Profit in 2026 
Nvidia Secures $500 Billion AI Infrastructure Push With Wall Street Giants 
Trump Media Says Truth API Draws 10+ Customers as Conflict Concerns Grow 
AMP Shares Surge 13% After Strong Profit and A$150 Million Buyback 
Hims & Hers Shares Fall as GLP-1 Costs Widen Q2 Loss 
Hanwha Offers Up to $1.2 Billion for Austal US Business 
Daimler Truck Q2 Profit Falls 18%, 2026 Outlook Raised 
Mercedes-Benz Stock Offers Deep-Value Potential as Citi Sees Recovery Catalysts 
Natura Q2 Profit Plunges 92% as Financial Expenses Weigh on Earnings 
Sony, TSMC Eye $6.3 Billion Japan Chip Venture for Next-Gen Image Sensors 
Delta Flight Makes Emergency Landing in Atlanta After Cockpit Fumes Reported 
Dublin, Feb. 16, 2018 -- The "RNAi - Technologies, Markets and Companies" report from Jain PharmaBiotech has been added to ResearchAndMarkets.com's offering.
Various RNAi technologies are described, along with design and methods of manufacture of siRNA reagents. These include chemical synthesis by in vitro transcription and use of plasmid or viral vectors. Other approaches to RNAi include DNA-directed RNAi (ddRNAi) that is used to produce dsRNA inside the cell, which is cleaved into siRNA by the action of Dicer, a specific type of RNAse III. MicroRNAs are derived by processing of short hairpins that can inhibit the mRNAs. Expressed interfering RNA (eiRNA) is used to express dsRNA intracellularly from DNA plasmids.
Regulatory, safety and patent issues are discussed. Side effects can result from unintended interaction between an siRNA compound and an unrelated host gene. If RNAi compounds are designed poorly, there is an increased chance for non-specific interaction with host genes that may cause adverse effects in the host. However, there are no major safety concerns and regulations are in preliminary stages as the clinical trials are still ongoing and there are no marketed products. Many of the patents are still pending.
The markets for RNAi are difficult to define as no RNAi-based product is approved yet but several are in clinical trials. The major use of RNAi reagents is in research but it partially overlaps that of drug discovery and therapeutic development. Various markets relevant to RNAi are analyzed from 2017 to 2027. Markets are also analyzed according to technologies and use of siRNAs, miRNAs, etc.
Profiles of 162 companies involved in developing RNAi technologies are presented along with 233 collaborations. They are a mix of companies that supply reagents and technologies (nearly half of all) and companies that use the technologies for drug discovery. Out of these, 33 are developing RNAi-based therapeutics and 36 are involved in microRNAs. The bibliography contains selected 650 publications that are cited in the report. The text is supplemented with 39 tables and 15 figures.
Key Topics Covered:
Executive Summary
1. Technologies for suppressing gene function
2. RNAi Technologies
3. MicroRNA
4. Methods of delivery in RNAi
5. RNAi in Research
6. RNAi in drug discovery
7. Therapeutic applications of RNAi
8. Safety, regulatory and patent issues
9. Markets for RNAi Technologies
10. Companies involved in RNAi Technologies
11. References
For more information about this report visit https://www.researchandmarkets.com/research/3zzljg/global_rnai?w=12
CONTACT: ResearchAndMarkets.com
Laura Wood, Senior Manager
[email protected]
For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related Topics: Genomics
